Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on June 7, 2022. The report details a material amendment to a royalty purchase agreement and an update regarding the company's compliance with Nasdaq listing requirements.
Key Financial Metrics and Liquidity
- Stockholders' Equity: The company reported a stockholders' deficit of approximately $5.9 million as of March 31, 2022.
- Accounting Gain: The company recognized a gain of approximately $35 million, representing the remaining liability on its balance sheet related to the royalty agreement amendment.
- Projected Milestone Payments: The company anticipates earning up to $22.5 million in additional milestone payments tied to RUXIENCE net sales thresholds ($12.5 million for 2022 and $10 million for 2023).
- Residual Royalties: The company does not anticipate receiving substantial residual royalty payments based on current sales performance and projections.
Material Changes and Events
Royalty Purchase Agreement Amendment
On June 7, 2022, Aptevo amended its agreement with an entity managed by HealthCare Royalty Management, LLC (HCR). The amendment stipulates that Aptevo will forego its right to receive 50% of RUXIENCE royalty revenue once HCR receives aggregate payments totaling 190% of the $35 million upfront payment plus any milestone payments. This change resulted in the immediate recognition of the remaining liability as a gain.
Nasdaq Compliance Status
The company previously received notice of non-compliance with Nasdaq Listing Rule 5550(b)(1) regarding the minimum $2.5 million stockholders' equity requirement. Following the recognition of the $35 million gain from the royalty amendment, the company believes it now satisfies this requirement as of the filing date. Nasdaq has granted an extension through September 28, 2022, to evidence full compliance.
Outlook, Risks, and Management Commentary
- Compliance Outlook: Management anticipates evidencing compliance with the Nasdaq stockholders' equity rule at the date of the next periodic report.
- Delisting Risk: If the company fails to evidence compliance in its next periodic report, it may be subject to delisting, subject to the right to request a hearing before an independent Panel.
- Revenue Expectations: While residual royalty payments are not expected to be substantial, the company expects to achieve the sales thresholds necessary to trigger the $22.5 million in milestone payments.
Investor Verification Checklist
- Verify the exact calculation of the $35 million gain and its impact on the current stockholders' equity position.
- Confirm the specific net sales thresholds required to trigger the $12.5 million (2022) and $10 million (2023) milestone payments.
- Monitor the upcoming periodic report to confirm formal evidence of compliance with Nasdaq Listing Rule 5550(b)(1).
- Review the terms of the amended royalty agreement to understand the long-term implications of forfeiting 50% of residual royalties.